Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis Over 56 Weeks from a Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study

Authors

A Deodhar
Alice B. Gottlieb, New York Medical CollegeFollow
W-H Boehricke
B Dong
Y Wang
Y Zhuang
W Barchuk
X L. Xu
H Hsia

Document Type

Abstract

Publication Date

6-2018

Journal Title

Annals of Rhuematic Diseases

Department

Dermatology

Recommended Citation

Deodhar, A., Gottlieb, A. B., Boehricke, W., Dong, B., Wang, Y., Zhuang, Y., Barchuk, W., Xu, X. L., & Hsia, H. (2018). Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis Over 56 Weeks from a Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study. Annals of Rhuematic Diseases, 77 (Suppl. 2), 201. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/232